Expertise in
72
conditions

Dr. Sridhar Bolla

Hematology | Oncology
Hendricks Oncology
8244 E US Highway 36 Ste 1340, 
Avon, IN 
Accepting New Patients
Offers Telehealth
Expertise in
72
conditions
Hendricks Oncology
8244 E US Highway 36 Ste 1340, 
Avon, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sridhar Bolla is a Hematologist and an Oncologist in Avon, Indiana. Dr. Bolla is highly rated in 72 conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration. Dr. Bolla is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Putnam County Hospital
Indiana University Health
Hendricks Regional Health
Iu Health West Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 14 Less Insurance Carriers -

Locations

Hendricks Oncology
8244 E US Highway 36 Ste 1340, Avon, IN 46123
Other Locations
Hendricks Oncology
100 Hospital Ln Ste 320, Danville, IN 46122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 2 Less Clinical Trials

1 Total Publications

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
Journal: Gynecologic oncology case reports
Published: March 25, 2013
Similar Doctors
Expertise in
30
conditions
Dr. Daniel Rushing
Hematology | Oncology
Expertise in
30
conditions
Dr. Daniel Rushing
Hematology | Oncology

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (17.2 miles away)
317-948-8310
Languages Spoken:
English
See accepted insurances

Daniel Rushing is a Hematologist and an Oncologist in Indianapolis, Indiana. Dr. Rushing is highly rated in 30 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Epithelioid Sarcoma, and Bone Tumor.

Expertise in
7
conditions
Dr. Steven Rhodes
Hematology | Oncology
Expertise in
7
conditions
Dr. Steven Rhodes
Hematology | Oncology

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (17.2 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances

Steven Rhodes is a Hematologist and an Oncologist in Indianapolis, Indiana. Dr. Rhodes is highly rated in 7 conditions, according to our data. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Optic Glioma, and RASopathies.

Expertise in
9
conditions
Dr. Seethal Jacob
Hematology | Oncology
Expertise in
9
conditions
Dr. Seethal Jacob
Hematology | Oncology

Office

575 Riley Hospital Dr Ste 3270, 
Indianapolis, IN 
 (18.1 miles away)
317-944-2143
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Seethal Jacob is a Hematologist and an Oncologist in Indianapolis, Indiana. Dr. Jacob has been practicing medicine for over 17 years is highly rated in 9 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Pacemaker Implantation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bolla's expertise for a condition
ConditionClose
    View All 26 Distinguished Conditions
    View All 46 Advanced Conditions
    View All 151 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile